Patented peptides for anti-aging care and sensitive skin.

BASF deployed Peptovitae, a series of four proprietary peptides that represent a new generation of scientifically-developed biomimetic peptides.

“Increasingly, consumers are looking for safe and effective solutions based on high-efficacy skin care regimens as an alternative to procedure-based treatments to meet their personal skincare needs,” said Eunice. Jeong, Regional Market Development Manager, Personal Care Solutions, Household Chemicals, BASF Asia-Pacific. “The strong growth of dermocosmetics in China and the doubling of dermocosmetics’ share of the global beauty market over the past 15 years is a testament to the robust growth of peptide-containing products and consumer shifts towards biomimetic skincare regimens.”

Peptovitae was developed in Asia through an exclusive relationship with Caregen, a Korea-based company and world leader in the research and development of biomimetic peptides. The Peptovitae series addresses a wider range of skin concerns than those traditionally associated with the use of peptides. These new bioactives from BASF’s skincare creations address personal care skin benefits related to fighting the signs of aging (Peptovitae Matrix), improving skin radiance (Peptovitae Bright), soothing skin prone to dryness and itchiness (Peptovitae Derma) as well as soothing and hydrating skin (Peptovitae Clear).

The liposome-based dual-layer encapsulation system used in the Peptovitae series allows finished products to deliver the benefits of these skin-like biomimetic peptides.

Developed in Asia for the needs of global consumers, Peptovitae provides unique biomimetic peptides through partnership with Caregen, a leader in biomimetic peptides. The resulting products offer powerful and proven efficacy in meeting consumers’ skin needs.

“BASF has tailored these peptides to ensure they meet cosmetics industry standards, making these products available to our customers and consumers,” said Viju Jose, Vice President, Personal Care Solutions, care chemicals, BASF Asia-Pacific.

About Thomas Hereford

Check Also

Pierre Fabre and Lonza enter into a manufacturing agreement for the W0180 antibody

Lonza will provide clinical drug manufacturing for W0180, an oncology drug candidate discovered by Pierre …